SCHEMBL267767

SCHEMBL267767

Cc1ccc(C=NNC(=O)c2scc(C)c2NC(=O)c2cccc(CN3CCN(CCO)CC3)c2)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 4/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
ENPP2 Q13822 3/20 0.38
ACKR3 P25106 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGDS O60760 1/20 0.38
ACHE P22303 2/20 0.37
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267766 1.00 SLC34A2 (0.41) SLC34A2CA1CA2CA7CA9
SCHEMBL268167 0.93 NPC1 (0.42) SLC34A2CA1CA2CA7CA9
SCHEMBL268168 0.93 NPC1 (0.42) SLC34A2CA1CA2CA7CA9
SCHEMBL267346 0.92 ENPP2 (0.46) SLC34A2CA1CA2CA7CA9
SCHEMBL267347 0.92 ENPP2 (0.46) SLC34A2CA1CA2CA7CA9
SCHEMBL267508 0.91 PKM (0.46) SLC34A2ENPP2ACKR3ALDH1A1POLB
SCHEMBL267507 0.91 PKM (0.46) SLC34A2ENPP2ACKR3ALDH1A1POLB
SCHEMBL266463 0.89 SLC34A2 (0.51) SLC34A2ENPP2ACKR3
SCHEMBL266462 0.89 SLC34A2 (0.51) SLC34A2ENPP2ACKR3
SCHEMBL266227 0.88 SLC34A2 (0.46) SLC34A2ENPP2ACKR3ALDH1A1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885CA1 1483/4885CA2 135/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885CA1 1432/4885CA2 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.